Nuvig drops a Phase 2 trial; Cerevance reports Parkinson's progress

Phase 2negativeNVG-2089Negative

AI Analysis

Summary

Nuvig Therapeutics terminated a Phase 2 trial of NVG-2089 in chronic inflammatory demyelinating polyneuropathy. Cerevance reported progress in Parkinson's disease.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Phase 2 trial terminated

Importance:5/10

Sentiment:

-0.70

trial terminationPhase 2Nuvig TherapeuticsNVG-2089CIDPCerevanceParkinson's disease

Read the original article

Published by Endpoints News on October 7, 2026 3:20 PM

Read Original